Overview
Study information
| Network: | CAVD |
| Grant Affiliation: | Letvin: rAdenoviral & rMycobacterial Vector Immunogens |
| Strategy: | Vector vaccines (viral or bacterial) |
| Study Type: | Pre-Clinical NHP |
| Species: | Rhesus macaque |
| Stage: | Assays Completed |
| Study Start Date: | 2010-06-06 |
| Study Made Public: | 2013-07-25 |
Title
rBCG Vaccines
Description
CAVD 247 is a non-human primate study comparing 2nd generation live recombinant Bacillus Calmette Guérin (rBCG) with wildtype BCG in BCG/NYVAC prime/boost regimens. The animals immunized with the rBCG mutants showed enhanced immunogenicity in comparison to animals immunized with the parental rBCG Danish control.
Sign in to see full information about this study and to download study data.
Products
BCG Dan WT BCG Dan10 BCG Dan10 AF25 BCG J13R10 BCG J13R7 rNYVAC-SIV-Gag-Pol vp1042 (Mac142) rDNA SIV-Gag-Pol-NefIntegrated data
No integrated data is available for this study.
Non-integrated data
No non-integrated data is available for this study.